NCT03952078 2025-04-16A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaCorvus Pharmaceuticals, Inc.Phase 1 Active not recruiting151 enrolled
NCT03703375 2024-07-08Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgenePhase 3 Active not recruiting93 enrolled 19 charts